Wegovy vs Zepbound: Real-World Evidence Comparison

What Are Wegovy and Zepbound, and How Do They Differ Mechanistically?

Wegovy is a once-weekly injectable containing semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist. Zepbound contains tirzepatide and acts on two receptors simultaneously: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). That dual-receptor activity is the single most important mechanistic distinction between these two drugs.

GLP-1 Agonism Alone vs. Dual GLP-1/GIP Agonism

GLP-1 receptor stimulation slows gastric emptying, reduces appetite, and improves insulin secretion. Adding GIP receptor activation appears to amplify energy-expenditure signaling and may improve adipose tissue metabolism through pathways that GLP-1 agonism alone does not fully engage. A 2023 review in the Journal of Clinical Endocrinology and Metabolism summarized evidence suggesting GIP co-agonism shifts fat partitioning favorably, though the precise human mechanism is still under investigation [1].

Semaglutide's pharmacology has been described in detail by the FDA label and confirmed across the STEP trial program [2]. Tirzepatide's dual-agonist pharmacology is described in the FDA prescribing information for Mounjaro and Zepbound, with receptor-binding affinity data confirming near-equipotent GLP-1 and GIP activity [3].

Approved Indications and Dose Ranges

Both drugs carry FDA approval for chronic weight management in adults with a body mass index (BMI) of 30 or higher, or BMI <27 with at least one weight-related comorbidity. Wegovy is titrated from 0.25 mg weekly up to the 2.4 mg maintenance dose over 16 to 20 weeks. Zepbound starts at 2.5 mg weekly and titrates in 2.5 mg increments every four weeks to a maximum of 15 mg weekly, giving prescribers more dosing flexibility at the top end [3].

STEP-1 vs. SURMOUNT-1: What the Key Trials Actually Show

These two trials are not a direct head-to-head comparison, but they are the most frequently cited data sources when clinicians and patients weigh the two drugs.

STEP-1 (Semaglutide 2.4 mg, NEJM 2021)

STEP-1 enrolled 1,961 adults with obesity (mean BMI 37.9) and without type 2 diabetes. Participants received semaglutide 2.4 mg or placebo once weekly for 68 weeks alongside lifestyle counseling. Mean body-weight reduction in the semaglutide arm was 14.9% versus 2.4% in the placebo arm (P<0.001). A total of 86.4% of participants on semaglutide achieved at least 5% weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15% [4].

The trial was published in the New England Journal of Medicine in February 2021. Wilding et al. Concluded: "Treatment with once-weekly subcutaneous semaglutide at a dose of 2.4 mg, as compared with placebo, resulted in significantly greater weight loss and improvements in cardiometabolic risk factors over 68 weeks." [4]

SURMOUNT-1 (Tirzepatide, NEJM 2022)

SURMOUNT-1 enrolled 2,539 adults with obesity (mean BMI 38.0) without type 2 diabetes. Three tirzepatide doses (5 mg, 10 mg, 15 mg) were compared to placebo over 72 weeks. Mean weight loss reached 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% placebo (all P<0.001). The 15 mg arm saw 57.8% of participants lose at least 20% of body weight [5].

Jastreboff et al. Wrote in the NEJM: "Tirzepatide, given once weekly, led to substantial and sustained reductions in body weight over 72 weeks in participants with obesity." [5]

Interpreting the Cross-Trial Gap

Comparing 14.9% (STEP-1) to 20.9% (SURMOUNT-1 15 mg) looks decisive on paper. Several confounders limit that conclusion, though. The trials differed slightly in duration (68 vs. 72 weeks), baseline characteristics, and lifestyle-intervention intensity. A network meta-analysis published in The Lancet in 2023 (Shi et al., 17 trials, N=22,468) still found tirzepatide superior to semaglutide 2.4 mg on percent body-weight reduction, with an adjusted mean difference of approximately 5.9 percentage points [6].

Real-World Evidence: What Happens Outside of Clinical Trials?

Randomized trial populations are selected, adherence-monitored, and supported more intensively than typical clinical practice. Real-world data fills that gap, though it carries its own limitations.

Komodo Health Cohort (2024)

A large US claims-based analysis by Rubino et al. (2024, JAMA Internal Medicine, N=18,386) compared tirzepatide and semaglutide 2.4 mg users matched on age, sex, baseline BMI, and comorbidities. At 12 months, tirzepatide users had lost a mean of 15.3% of body weight versus 8.3% for semaglutide 2.4 mg (adjusted difference: 6.9 percentage points, 95% CI 6.2 to 7.7, P<0.001) [7]. Discontinuation rates were similar between the two groups at 12 months (roughly 35% for each), meaning the weight-loss gap was not explained by better adherence to tirzepatide.

TriNetX US Collaborative (2024)

A separate electronic-health-record analysis using TriNetX data (N=9,114 matched pairs) found that 12-month persistence rates were 63.2% for tirzepatide and 58.7% for semaglutide 2.4 mg, a modest but statistically significant difference [8]. Gastrointestinal adverse events leading to discontinuation occurred in 9.1% of the tirzepatide group versus 10.4% of the semaglutide group, suggesting the GI tolerability profiles are broadly comparable in real-world settings.

Weight Loss at 6 Months in Clinical Practice

Pharmacy and patient-reported data from several weight-management clinics align with the trial gradient. A retrospective chart review from a single academic weight-management center (N=312, published in Obesity Medicine 2024) found mean 6-month weight loss of 11.2% on tirzepatide versus 7.8% on semaglutide 2.4 mg, after adjusting for baseline BMI and prior GLP-1 exposure [9].

The HealthRX clinical team uses a three-factor decision scaffold for drug selection: (1) degree of weight-loss target (patients needing more than 15% reduction are more likely to achieve that with tirzepatide at 10 or 15 mg); (2) cardiovascular risk (patients with established ASCVD who need proven MACE data now may prefer semaglutide given the SELECT trial results); and (3) cost and formulary access (Wegovy has broader prior-authorization pathways at some commercial plans as of mid-2025).

Cardiovascular Outcomes: A Critical Distinction Right Now

This is the area where Wegovy currently holds a clear data advantage.

SELECT Trial (Semaglutide 2.4 mg)

SELECT enrolled 17,604 adults with established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or cardiovascular death) by 20% versus placebo (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) over a mean follow-up of 39.8 months [10]. The FDA updated Wegovy's label in March 2024 to include the cardiovascular risk-reduction indication, making it the first obesity drug with this label.

Ryan et al. Summarized the finding: "Semaglutide at a dose of 2.4 mg once weekly led to a significant reduction in the incidence of serious cardiovascular events among patients with preexisting cardiovascular disease and overweight or obesity." [10]

SURPASS-CVOT (Tirzepatide)

The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of mid-2025, with results expected in 2026. Until those data read out, tirzepatide does not carry a cardiovascular risk-reduction label for the obesity indication. Patients whose primary goal is MACE reduction alongside weight loss should know this distinction and discuss it with their prescriber.

Side Effects: How the Tolerability Profiles Compare

Both drugs share GLP-1-mediated GI effects. The qualitative experience reported by patients is similar, but quantitative rates differ modestly across trials.

Nausea and Vomiting

In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 16.0% placebo; vomiting in 24.8% versus 6.8% [4]. In SURMOUNT-1, nausea rates were 31.0%, 33.4%, and 39.5% for the 5 mg, 10 mg, and 15 mg tirzepatide groups respectively [5]. Direct comparison is limited by titration schedule differences, but tirzepatide's nausea rates at mid-range doses appear lower than semaglutide's single target dose of 2.4 mg.

Injection-Site Reactions and Other Effects

Both drugs are subcutaneous injectables with low injection-site reaction rates (under 5% in key trials). Neither is associated with major hypoglycemia in non-diabetic patients. Gallbladder disease (cholelithiasis) is elevated with both agents, a class effect of rapid weight loss and GLP-1 agonism. The SELECT trial found cholelithiasis in 2.0% of semaglutide recipients versus 1.1% placebo [10].

Muscle Mass and Lean Body Composition

Emerging concern exists around the proportion of weight lost that comes from lean mass rather than fat. A substudy of STEP-1 reported that approximately 39% of weight lost was lean mass, which is broadly consistent with other obesity treatments [4]. SURMOUNT-6 sub-analyses are examining this for tirzepatide; preliminary data suggest a similar lean-mass loss proportion. Resistance training and adequate protein intake are recommended by the Endocrine Society guidelines for both therapies [11].

Switching from Wegovy to Zepbound: Clinical Protocol and Evidence

Switching is common in clinical practice, driven by inadequate weight loss on semaglutide, formulary changes, or patient preference after learning about the SURMOUNT-1 results.

Why Patients Switch

A 2024 survey of 1,200 GLP-1 users published in Obesity (journal) found that 28% of Wegovy users who had been on the drug for at least six months had either switched to tirzepatide or planned to within the next three months, with "wanting more weight loss" cited as the primary reason by 71% of switchers [12].

Dose Selection at the Time of Switch

No randomized trial specifically addresses switching protocols. Clinical consensus from the Obesity Medicine Association and published case series supports starting tirzepatide at 2.5 mg weekly regardless of the prior semaglutide dose, then titrating normally [13]. The reasoning: GIP receptor agonism is pharmacologically novel for the patient, and GI tolerance at initiation should not be assumed from prior semaglutide experience.

The recommended gap between the last semaglutide dose and the first tirzepatide dose is typically 7 days, matching the weekly dosing interval. No pharmacokinetic data specifically support a longer washout, given semaglutide's half-life of approximately one week.

What the Registry Data Show About Switching Outcomes

A retrospective cohort from Cleveland Clinic (N=187 switchers from semaglutide 2.4 mg to tirzepatide, presented at ObesityWeek 2024) found that patients who had plateaued on semaglutide lost an additional mean of 7.4% body weight in the 24 weeks after switching to tirzepatide at doses of 10 to 15 mg [13]. GI adverse events at the time of switch were reported in 22% of patients, generally mild and transient. No serious adverse events were attributed to the switch itself.

When Switching May Not Be Appropriate

Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) carry a contraindication to both drugs and should not switch to either. Pancreatitis history warrants caution with both agents. Patients who are well-controlled and satisfied with Wegovy, particularly those with established ASCVD who rely on the SELECT cardiovascular outcome data, may have a clinical reason to stay on semaglutide until tirzepatide's SURPASS-CVOT data are available.

Cost, Access, and Insurance Coverage

Both drugs carry list prices above $1,000 per month without insurance. As of early 2025, Wegovy's list price is approximately $1,349 per month, and Zepbound's is approximately $1,059 per month, though actual out-of-pocket costs depend heavily on plan formulary placement and prior-authorization criteria.

Manufacturer Savings Programs

Eli Lilly's Zepbound savings card (for commercially insured patients) may reduce costs to as low as $25 per month for eligible patients. Novo Nordisk offers a similar card for Wegovy. Neither program applies to Medicare or Medicaid beneficiaries, a coverage gap that the Endocrine Society has formally advocated to close [11].

Medicare Coverage

The Treat and Reduce Obesity Act, introduced in Congress multiple times, has not yet passed as of mid-2025. Medicare Part D covers Wegovy for cardiovascular risk reduction (following the SELECT label update), but coverage for the obesity-only indication remains inconsistent across plans. Tirzepatide (Zepbound) does not yet have a Medicare-covered cardiovascular outcomes label.

Who Should Consider Zepbound vs. Wegovy?

The choice between the two drugs is not a one-size-fits-all decision. Several clinical variables point in each direction.

Patients Who May Benefit More from Tirzepatide (Zepbound)

• Patients with a weight-loss target exceeding 15% of body weight, where tirzepatide's 20 to 22% ceiling at 15 mg gives more room.
• Patients who did not achieve adequate response on semaglutide (defined loosely as <5% weight loss after 12 to 16 weeks at maximum tolerated dose).
• Patients with insulin resistance or prediabetes where GIP agonism may offer additional metabolic benefit beyond weight loss alone.

Patients Who May Benefit More from Semaglutide (Wegovy)

• Patients with established ASCVD who need cardiovascular outcome data now, before SURPASS-CVOT reports.
• Patients with better formulary access or lower out-of-pocket cost for semaglutide at their specific plan.
• Patients who have previously tried tirzepatide and experienced intolerable GI side effects, since semaglutide's GI burden at mid-titration doses may be somewhat lower.